natgillin/translations-raw huggingface dataset:
Discontinuation of IntronA therapy has not reversed thyroid dysfunction occurring during treatment (also see Thyroid supplemental monitoring specific for children and adolescents).
IntronA motnje delovanja žleze ščitnice, ki so se pojavile med terapijo, niso minile (glejte tudi Dodatno spremljanje žleze ščitnice pri otrocih in mladostnikih).
In patients who are in the plateau phase (more than 50 % reduction of myeloma protein) following initial induction chemotherapy, interferon alfa-2b may be administered as monotherapy, subcutaneously, at a dose of 3 million IU/m2 three times a week (every other day).
Pri bolnikih v fazi platoja (več kot 50 % zmanjšanje količine mielomskega proteina) po začetni uvajalni kemoterapiji lahko interferon alfa-2b aplicirate v obliki monoterapije, subkutano, v odmerku 3 milijone i.e./m2 trikrat na teden (vsak drugi dan).
Thyroid supplemental monitoring specific for children and adolescents Approximately 12 % of children treated with interferon alfa-2b and ribavirin combination therapy developed increase in thyroid stimulating hormone (TSH).
Dodatno spremljanje žleze ščitnice pri otrocih in mladostnikih Pri približno 12 % otrok, zdravljenih s kombinirano terapijo z interferonom alfa-2b in ribavirinom, se je pojavilo povečanje vrednosti tirotropnega hormona (TSH).
- if you have a history of seizures (convulsions).
- če ste imeli kdaj v preteklosti epileptične napade (konvulzije).
Periodic visual examinations during IntronA therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension.
Med zdravljenjem z zdravilom IntronA priporočamo redne preglede vida, še posebej pri bolnikih z boleznimi, ki so lahko povezane z retinopatijo, kot sta sladkorna bolezen ali hipertenzija.
Mutagenicity studies with interferon alfa-2b revealed no adverse events.
Raziskave mutagenosti interferona alfa-2b niso pokazale nobenih neželenih učinkov.
IntronA must be used cautiously in patients with debilitating medical conditions, such as those with a history of pulmonary disease (e.g., chronic obstructive pulmonary disease) or diabetes mellitus prone to ketoacidosis.
Zdravilo IntronA morate uporabljati previdno pri bolnikih z izčrpavajočimi bolezenskimi stanji, npr. pri tistih s pljučno boleznijo v anamnezi (npr. kronično obstruktivno pljučno boleznijo) ali sladkorno boleznijo z nagnjenostjo h ketoacidozi.
High tumour burden is defined as having at least one of the following: bulky tumour mass (> 7 cm), involvement of three or more nodal sites (each > 3 cm), systemic symptoms (weight loss > 10 %, pyrexia > 38°C for more than 8 days, or nocturnal sweats), splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukaemia.
Velika tumorska obremenitev je opredeljena s tem, da ima bolnik najmanj enega od naslednjih znakov: obsežno tumorsko tvorbo (> 7 cm), prizadetost treh ali več skupin bezgavk (vsaka > 3 cm), sistemske simptome (zmanjšanje telesne mase > 10 %, zvišana telesna temperatura > 38 °C več kot 8 dni, nočno znojenje), splenomegalijo, ki sega pod popek, sindrom obstrukcije ali kompresije večjih organov, prizadetost orbite ali epiduralnih struktur, serozni izliv ali levkemijo.
IntronA is a sterile, stable, formulation of highly purified interferon alfa-2b produced by recombinant DNA techniques.
Zdravilo IntronA je sterilna, stabilna oblika visokoprečiščenega interferona alfa-2b, izdelanega s tehnikami rekombinantne DNA.
High doses of other forms of interferons alpha and beta are known to produce doserelated anovulatory and abortifacient effects in rhesus monkeys.
Tudi za velike odmerke drugih oblik interferonov alfa in beta je znano, da povzročijo od odmerka odvisne učinke v smislu izgube ovulacije ali splava pri opicah rhesus.
The combination of interferon alfa-2b and cytarabine (Ara-C) administered during the first 12 months of treatment has been demonstrated to significantly increase the rate of major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy.
Raziskave so pokazale, da kombinacija interferona alfa-2b in citarabina (Ara-C), uporabljena v prvih 12 mesecih zdravljenja, bistveno poveča delež večjega citogenetskega odziva in bistveno podaljša skupno preživetje po 3 letih v primerjavi z monoterapijo z interferonom alfa-2b.
Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis B viral replication (presence of DNA of hepatitis B virus (HBV-DNA) and hepatitis B antigen (HBeAg), elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and/or fibrosis.
Zdravljenje odraslih bolnikov s kroničnim hepatitisom B, ki imajo potrjeno replikacijo virusa hepatitisa B (prisotnost DNA virusa hepatitisa B (HBV-DNA) in antigen hepatitisa B (HBeAg)), povečano vrednost alanin-aminotransferaze (ALT) in histološko dokazano aktivno vnetje jeter in/ali fibrozo jeter.
Early intervention for re-emergence or development of psychiatric disorders and substance use is recommended.
V primeru ponovnega pojava ali novega nastanka psihiatričnih motenj in uživanja opojnih substanc je priporočljivo zgodnje ukrepanje.
Adequate hydration must be maintained in patients undergoing IntronA therapy since hypotension related to fluid depletion has been seen in some patients.
Pri bolnikih na terapiji z zdravilom IntronA morate vzdrževati ustrezno hidracijo, saj so pri nekaterih bolnikih opažali hipotenzijo zaradi izgube tekočine.
3 or ALT/AST rises to > 10 x upper limit of normal, discontinue interferon alfa-2b therapy.
3 ali se vrednost ALT/AST zviša na > 10-kratno zgornjo mejo normale, terapijo z interferonom alfa-2b ukinite.
A total of 345 interferon alpha relapse patients were treated in two clinical trials with IntronA monotherapy or in combination with ribavirin.
Skupaj 345 bolnikov z relapsom po zdravljenju z interferonom alfa je bilo zdravljenih v dveh kliničnih raziskavah z zdravilom IntronA, v monoterapiji ali v kombinaciji z ribavirinom.
IntronA has been classified as recombinant interferon alfa-2b.
IntronA je opredeljen kot rekombinantni interferon alfa-2b.
All but one of the paediatric subjects remained sustained virologic responders during long-term follow-up after completion of treatment with interferon alfa-2b plus ribavirin.
Pri vseh pediatričnih bolnikih razen pri enem se je trajni virološki odziv ohranil med dolgoročnim spremljanjem po zaključku zdravljenja z interferonom alfa-2b in ribavirinom.
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction assay (PCR) (> 100 copies/mL), a liver biopsy consistent with a histologic diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
Bolniki, primerni za vključitev v te raziskave, so imeli kronični hepatitis C, ki je bil potrjen s pozitivnim izvidom testa verižne reakcije s polimerazo za HCV-RNA (PCR) (> 100 kopij/ml), izvidom jetrne biopsije, ki je histološko potrdil diagnozo kroničnega hepatitisa brez drugega vzroka za kronični hepatitis, ter nenormalno serumsko vrednostjo ALT.
p value pegylated interferon alfa-2b (100 or c µg/week) + ribavirin
vrednost p pegiliran interferon alfa-2b (100 ali c µg/ teden) + ribavirin mg)
Included are hairy cell leukaemia, chronic myelogenous leukaemia, multiple myeloma, follicular lymphoma, carcinoid tumour, and malignant melanoma.
Te bolezni vključujejo dlakastocelično levkemijo, kronično mieloično levkemijo, multipli mielom, folikularni limfom, karcinoidni tumor in maligni melanom.
Among children and adolescents treated with IntronA in combination with ribavirin, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4 % vs 1 %) during treatment and during the 6-month follow-up after treatment.
Pri otrocih in mladostnikih, zdravljenih z zdravilom IntronA v kombinaciji z ribavirinom, so o samomorilnih mislih ali poskusu samomora poročali pogosteje kot pri odraslih (2,4 % v primerjavi z 1 %) med zdravljenjem in v času 6-mesečnega spremljanja bolnikov po zdravljenju.
Children and adolescents - Existence of, or history of severe psychiatric condition, particularly severe depression, suicidal ideation or suicide attempt.
Otroci in mladostniki - Obstoječa huda duševna bolezen ali huda duševna bolezen v anamnezi, še posebej huda depresija, samomorilne misli ali poskus samomora.
a: p value based on Cochran-Mantel Haenszel Chi square test. b: p value based on chi-square test. c: subjects < 75 kg received 100 µg/week pegylated interferon alfa-2b and subjects ≥ 75 kg received 150 µg/week pegylated interferon alfa-2b.
= milijonov mednarodnih enot; TIW = trikrat na teden a: vrednost p na podlagi Cochran-Mantel Haenszelovega hi-kvadrat testa b: vrednost p na podlagi testa hi-kvadrat c: Preiskovanci s telesno maso < 75 kg so prejemali pegilirani interferon alfa-2b v odmerku 100 µg/teden in preiskovanci s telesno maso ≥ 75 kg so prejemali pegilirani interferon alfa-2b v odmerku 150 µg/teden.
Pull back on the plunger slowly to draw the correct dose as prescribed by your doctor into the syringe (Diagram A).
Počasi povlecite bat nazaj, da v brizgo izvlečete ustrezen odmerek zdravila, kot ga je predpisal zdravnik (slika A).
Children and adolescents 3 to 16 years of age with compensated chronic hepatitis C and detectable HCV-RNA (assessed by a central laboratory using a research-based RT-PCR assay) were enrolled in two multicentre trials and received IntronA 3 MIU/m2 3 times a week plus ribavirin 15 mg/kg per day for 1 year followed by 6 months follow-up after-treatment.
Otroci in mladostniki, stari od 3 do 16 let, s kompenziranim kroničnim hepatitisom C in merljivimi količinami HCV RNA (kar je ocenil osrednji laboratorij z uporabo raziskovalnega testa RT-PCR), so bili vključeni v dve multicentrični preskušanji in so zdravilo IntronA prejemali v odmerku 3 mio i.e./m2 trikrat na teden skupaj z ribavirinom v odmerku 15 mg/kg na dan v obdobju enega leta, čemur je sledilo 6-mesečno spremljanje po zdravljenju.
10 million IU/mL
10 milijonov i.e./ml
Administration of IntronA in combination with other chemotherapeutic agents (e.g., Ara-C, cyclophosphamide, doxorubicin, teniposide) may lead to increased risk of toxicity (severity and duration), which may be life-threatening or fatal as a result of the concomitantly administered medicinal product.
Uporaba zdravila IntronA skupaj z drugimi kemoterapevtiki (npr. Ara-C, ciklofosfamidom, doksorubicinom, tenipozidom) lahko poveča tveganje toksičnosti (tako jakost kot trajanje), ki je lahko smrtno nevarna ali povzroči smrt zaradi sočasno danega zdravila.
Press the injection site with a small bandage or sterile gauze if necessary for several seconds.
Po potrebi za nekaj sekund pritisnite na mesto injiciranja z majhno obvezo ali sterilno gazo.
Administration of IntronA in combination with other chemotherapeutic agents (e.g., Ara-C, cyclophosphamide, doxorubicin, teniposide) may lead to increased risk of toxicity (severity and duration) (see section 4.4).
Uporaba zdravila IntronA skupaj z drugimi kemoterapevtiki (npr. Ara-C, ciklofosfamidom, doksorubicinom, tenipozidom) lahko poveča tveganje za toksičnost zdravila (tako jakost kot trajanje) (glejte poglavje 4.4).
As in adult patients, children and adolescents experienced other psychiatric adverse events (e.g., depression, emotional lability, and somnolence).
Tako kot pri odraslih bolnikih so se tudi pri otrocih in mladostnikih pojavili drugi psihiatrični neželeni učinki (npr. depresija, čustvena labilnost in zaspanost).
Table 1 Adverse reactions reported during clinical trials or following the marketing use of IntronA alone or in combination with ribavirin
Preglednica 1 Neželeni učinki, o katerih so poročali med kliničnimi preskušanji ali v obdobju trženja za zdravilo IntronA samo ali v kombinaciji z ribavirinom
IntronA is presented as a solution for injection or infusion.
Zdravilo IntronA je na voljo kot raztopina za injiciranje ali infundiranje.
At the beginning of treatment with IntronA, you may experience a flu-like reaction, with fever, fatigue, headache, muscle ache, joint pain and chills/rigors.
Na začetku zdravljenja z zdravilom IntronA boste lahko imeli gripi podobno reakcijo z zvišano telesno temperaturo, utrujenostjo, glavobolom, mišičnimi bolečinami, bolečinami v sklepih in mrzlico ali tresenjem.
Therapy may continue for as long as the patient responds to interferon alfa-2b treatment.
Zdravljenje lahko nadaljujete vse dokler se bolnik odziva na interferon alfa-2b.
The population enrolled mainly consisted of children with mild to moderate hepatitis C. Due to the lack of data in children with severe progression of the disease, and the potential for undesirable effects, the benefit/risk of the combination of peginterferon alfa-2b with ribavirin needs to be carefully considered in this population (see peginterferon alfa-2b and ribavirin SPCs section 4.4).
Populacija, vključena v preskušanje, je bila sestavljena predvsem iz otrok z blagim do zmernim hepatitisom C. Zaradi pomanjkanja podatkov pri otrocih z močno napredovalo boleznijo in zaradi nevarnosti za pojav neželenih učinkov je treba pri tej skupini bolnikov skrbno pretehtati razmerje med tveganji in koristmi zdravljenja s kombinacijo peginterferona alfa-2b in ribavirina (glejte SPC-ja za peginterferon alfa-2b in ribavirin, poglavje 4.4).
Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorders, mania, confusion and alterations of mental status have been observed with alpha interferons.
Pri alfa interferonih so opažali tudi druge učinke na CŽS, vključno z agresivnim obnašanjem (ki je včasih usmerjeno proti drugim, kot je ideja o umoru), bipolarno motnjo, manijo, zmedenostjo in spremembami duševnega statusa.
Interferon alfa-2b has been shown to have abortifacient effects in Macaca mulatta (rhesus monkeys) at 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU/m2.
Za interferon alfa-2b so študije pokazale, da povzroča splav pri opicah rhesus (Macaca mulatta), če ga prejemajo v odmerku, ki je 90 oz. 180-krat večji od priporočenega intramuskularnega ali subkutanega odmerka 2 milijona i.e./m2.
Very rarely reported side effects: low blood pressure, puffy face, diabetes, leg cramps, back pain, kidney problems, nerve damage, bleeding gums, aplastic anaemia.
Zelo redko poročani neželeni učinki: nizek krvni tlak, zabuhel obraz, sladkorna bolezen, krči v nogah, bolečine v hrbtu, težave z ledvicami, poškodbe živcev, krvavitev iz dlesni, aplastična anemija.
Long-Term efficacy data
Dolgoročni podatki o učinkovitosti zdravila
Chronic Hepatitis C - Combination therapy with ribavirin In clinical trials of 118 children and adolescents (3 to 16 years of age), 6 % discontinued therapy due to adverse reactions.
Kronični hepatitis C - kombinirano zdravljenje z ribavirinom V kliničnih preskušanjih pri 118 otrocih in mladostnikih (starih od 3 do 16 let) je bilo pri 6 %
Once opened, the medicine may be stored for a maximum of 28 days at 2ºC - 8ºC.
Po odpiranju lahko zdravilo shranjujete največ 28 dni pri temperaturi od 2 do 8 ºC.
As with all parenteral medicinal products, prior to administration inspect IntronA, solution for injection or infusion, visually for particulate matter and discolouration.
Kot velja za vsa parenteralna zdravila, morate pred uporabo zdravilo IntronA, raztopino za injiciranje ali infundiranje, vizualno pregledati in preveriti, da ne vsebuje delcev in da ni obarvana.
If you are prescribed IntronA in combination with another medicine, please refer also to the Package Leaflet of the medicine to be used in combination.
Če vam predpiše zdravilo IntronA v kombinaciji z drugim zdravilom, prosimo, preberite tudi Navodilo za uporabo za drugo zdravilo.
Sarcoidosis, exacerbation of sarcoidosis Systemic lupus erythematosus, vasculitis, rheumatoid arthritis (new or aggravated), Vogt-Koyanagi-Harada syndrome, acute hypersensitivity reactions including urticaria, angioedema, bronchoconstriction, anaphylaxis
sarkoidoza, poslabšanje sarkoidoze sistemski eritematozni lupus, vaskulitis, revmatoidni artritis (nov pojav ali poslabšanje obstoječega), sindrom VogtKoyanagi-Harada, akutne preobčutljivostne reakcije vključno z urtikarijo, angioedemom, bronhokonstrikcijo in anafilaksijo
How to use IntronA
Kako uporabljati zdravilo IntronA
Table 4 Sustained virological response based on genotype after IntronA in combination with ribavirin versus pegylated interferon alfa-2b in combination with ribavirin in HCV/HIV co-infected patients Study 1
Preglednica 4 Trajni virološki odziv glede na genotip po uporabi zdravila IntronA v kombinaciji z ribavirinom v primerjavi z uporabo pegiliranega interferona alfa-2b v kombinaciji z ribavirinom pri bolnikih, ki so bili sočasno okuženi z virusoma HCV in HIV Študija 1
Malignant melanoma, induction therapy: 20 million IU/m 2, intravenously, given daily for 5 days a week for a 4 week period.
Maligni melanom, začetno zdravljenje: 20 milijonov i.e./m 2, intravensko vsak dan, 5 dni na teden v času
Table 3 Sustained virologic response rates with IntronA + ribavirin (one year of treatment) by genotype and viral load
Preglednica 3 Deleži trajnega virološkega odziva pri uporabi zdravila IntronA in ribavirina (enoletno zdravljenje) glede na genotip in virusno obremenitev
Replace the needle guard and place the syringe with the needle on a flat surface.
Na iglo ponovno namestite zaščitni pokrovček ter brizgo z iglo odložite na ravno površino.
Urine levels of interferon were below the detection limit following each of the three routes of administration.
Koncentracija interferona v urinu je bila pod mejo detekcije pri vseh treh omenjenih načinih uporabe zdravila.
(affects 1 to 10 users in 10,000)
(pojavijo se pri 1 do 10 bolnikih od 10.000 bolnikov)
IntronA alone or in combination with ribavirin has been studied in 4 randomised Phase III clinical trials in 2,552 interferon-naïve patients with chronic hepatitis C. The trials compared the efficacy of IntronA used alone or in combination with ribavirin.
Zdravilo IntronA v monoterapiji ali v kombinaciji z ribavirinom so preučevali v 4 randomiziranih kliničnih raziskavah tretje faze pri 2.552 bolnikih, ki še niso bili zdravljeni z interferonom in so imeli kronični hepatitis C. V teh raziskavah so primerjali učinkovitost zdravila IntronA v monoterapiji ali v kombinaciji z ribavirinom.
If you are a male patient, you or your partner must use an effective contraceptive during the time you are taking ribavirin and for 7 months after stopping treatment.
Če ste moški, morate vi ali vaša partnerka uporabljati učinkovito kontracepcijo v času jemanja ribavirina in še 7 mesecev po zaključku zdravljenja.
In combination therapy with ribavirin, take notice of the respective informing texts of ribavirin containing medicinal products.
V primeru kombiniranega zdravljenja z ribavirinom morate upoštevati tudi ustrezne informacije o zdravilu, ki vsebuje ribavirin.
IntronA is available in nine different pack sizes: - Pack of 1 vial
Zdravilo IntronA je na voljo v devetih različnih pakiranjih: 1 viala,
Additionally, patients treated with IntronA and ribavirin combination therapy and zidovudine could be at increased risk of developing anaemia (low number of red blood cells).
Pri bolnikih, zdravljenih z zdravilom IntronA v kombinaciji z ribavirinom in zidovudinom, se lahko poveča tveganje za pojav anemije (majhno število rdečih krvnih celic).
pegylated interferon alfa2b (1.5 µg/kg/ week) + ribavirin (800 mg)
pegiliran interferon alfa-2b (1,5 µg/kg/ teden) + ribavirin (800 mg)
Based on the results of clinical trials, in which data are available for 12 months of treatment, it is recommended that patients be treated with IntronA in combination with ribavirin for at least 6 months.
Na podlagi rezultatov kliničnih raziskav, v katerih so bili na voljo podatki za 12-mesečno zdravljenje, priporočamo, da bolnike z zdravilom IntronA v kombinaciji z ribavirinom zdravite najmanj 6 mesecev.
§, hyperthyroidism Diabetes, aggravated diabetes
§, hipertiroidizem sladkorna bolezen, poslabšanje sladkorne bolezni
Thyroid dysfunction during treatment with interferon alfa-2b and ribavirin has been observed.
Opazili so motnje delovanja žleze ščitnice med zdravljenjem z interferonom alfa-2b in ribavirinom.
Toxicity was demonstrated in monkeys given 100 x 10
Študije pa so pokazale toksičnost interferona pri opicah, ki so prejemale 100 x 10
18 million IU/3 mL
18 milijonov i.e./3 ml
(See ribavirin capsules SPC for dose of ribavirin capsules and dose modification guidelines for combination therapy.
(Glede odmerjanja kapsul ribavirina in smernic za prilagoditev odmerka pri kombinirani terapiji glejte Povzetek glavnih značilnosti zdravila (SPC) za ribavirin.
The activity of IntronA is expressed in terms of IU, with 1 mg of recombinant interferon alfa-2b protein corresponding to 2.6 x l0
Aktivnost zdravila IntronA izražamo v i.e., pri čemer 1 mg rekombinantne beljakovine interferona alfa-2b ustreza 2,6 x 10
Within its shelf-life, for the purpose of transport, the solution can be kept at or below 25ºC for a period up to seven days before use.
V času roka uporabnosti z namenom transporta zdravila lahko raztopino shranjujete pri temperaturi do vključno 25 °C, in sicer do 7 dni pred uporabo.
Hypothyroidism Hyperthyroidism
hipotiroidizem hipertiroidizem
IntronA 18 MIU
IntronA 18 mio i.e.
The most commonly reported potentially life-threatening or fatal adverse events include mucositis, diarrhoea, neutropaenia, renal impairment, and electrolyte disturbance.
Najpogosteje poročani neželeni učinki, ki so lahko smrtno nevarni ali smrtni, so npr. mukozitis, driska, nevtropenija, ledvična okvara ter motnje elektrolitskega ravnovesja.
The abnormalities were controlled by conventional therapy for thyroid dysfunction.
Te so nadzorovali s konvencionalno terapijo za motnje delovanja ščitnice.
The following instructions explain how to inject IntronA yourself.
V spodnjih navodilih je opisano, kako si lahko sami injicirate zdravilo IntronA.
A wide variety of autoimmune and immune-mediated disorders have been reported with alpha interferons including thyroid disorders, systemic lupus erythematosus, rheumatoid arthritis (new or aggravated), idiopathic and thrombotic thrombocytopenic purpura, vasculitis, neuropathies including mononeuropathies (see also section 4.4).
Pri uporabi alfa interferonov so poročali o širokem razponu avtoimunih bolezni in bolezni imunskega sistema, npr. motnjah delovanja žleze ščitnice, sistemskem eritematoznem lupusu, revmatoidnem artritisu (novonastalem ali poslabšanem), idiopatski in trombotični trombocitopenični purpuri, vaskulitisu ter nevropatijah, vključno z mononevropatijami (glejte tudi poglavje 4.4).
Any patient developing pyrexia, cough, dyspnea or other respiratory symptoms must have a chest X-ray taken.
Pri vseh bolnikih, pri katerih se pojavijo zvišana telesna temperatura, kašelj, dispneja ali kakšni drugi respiratorni simptomi, morate opraviti rentgensko slikanje prsnega koša.
Change your injection site each time.
Pri vsakem injiciranju zamenjajte mesto injiciranja.
The appropriate dose of IntronA is withdrawn from the vial(s), added to 50 mL of 9 mg/mL (0.9 %) sodium chloride solution for injection in a PVC bag or glass bottle for intravenous use and administered over 20 minutes.
Ustrezni odmerek zdravila IntronA posesajte iz viale (vial), ga dodajte v 50 ml natrijevega klorida 9 mg/ml (0,9 %) raztopine za injekcije v PVC vrečki ali v steklenici za intravensko uporabo ter ga infundirajte bolniku v teku 20 minut.
25 million IU/2.5 mL
25 milijonov i.e./2,5 ml
Multiple-dose pharmacokinetic properties for IntronA injection and ribavirin capsules in children and adolescents with chronic hepatitis C, between 5 and 16 years of age, are summarized in Table 7.
Farmakokinetične lastnosti pri večkratnem odmerjanju zdravila IntronA injekcije in kapsul ribavirina pri otrocih in mladostnikih s kroničnim hepatitisom C v starosti od 5 do 16 let so povzete v Preglednici 7.
Be sure to discuss this with your doctor.
O tem se morate pogovoriti z zdravnikom.
Remove the syringe from the wrapping.
Brizgo vzemite iz ovoja.